Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer

Patrick M. Forde

Jonathan D. Spicer

Mariano Provencio

Hospital Universitario Puerta de Hierro, Madrid

Tetsuya Mitsudomi

Kindai University Faculty of Medicine, Ohno-Higashi, Osaka-Sayama, Japan

Mark M. Awad

Changli Wang

Tsinghua Center for Green Chemical Engineering Electrification, Department of Chemical Engineering

Shun Lu

Enriqueta Felip

Medical Oncology Service, Vall d’Hebron Institute of Oncology, Vall d’Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona

Scott J. Swanson

Brigham and Women’s Hospital, Boston

Julie R. Brahmer

Keith Kerr

Aberdeen Royal Infirmary, Aberdeen, United Kingdom

Janis M. Taube

Bloomberg–Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore

Tudor-Eliade Ciuleanu

Institutul Oncologic Prof. Dr. Ion Chiricuţă and University of Medicine and Pharmacy Iuliu Haţieganu, Cluj-Napoca, Romania

Fumihiro Tanaka

University of Occupational and Environmental Health, Kitakyushu, Japan

Gene B. Saylors

Charleston Oncology, Charleston, SC

Ke-Neng Chen

State Key Laboratory of Molecular Oncology, Peking University Cancer Hospital and Institute, Beijing

Hiroyuki Ito

Moishe Liberman

Centre Hospitalier de l’Université de Montréal, Montreal

Claudio Martin

Instituto Alexander Fleming, Buenos Aires

Stephen Broderick

Bloomberg–Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, Baltimore

Lily Wang

Junliang Cai

Bristol Myers Squibb, Princeton, NJ

Quyen Duong

Bristol Myers Squibb, Princeton, NJ

Stephanie Meadows-Shropshire

Bristol Myers Squibb, Princeton, NJ

Joseph Fiore

Bristol Myers Squibb, Princeton, NJ

Sumeena Bhatia

Bristol Myers Squibb, Princeton, NJ

Nicolas Girard

Institut Curie, Institut du Thorax Curie-Montsouris, Paris